A study of 479,000 adults found cyclists had 22% lower Alzheimer’s risk, 40% lower young-onset dementia risk, and measurably larger hippocampi than nonactive controls. Here’s what the data actually shows, the APOE caveat the headlines missed, and the negative RCT you should hold next to it.
In May 2026, three major papers landed on Lp(a) — the genetic cholesterol marker that 1 in 5 adults carry at risk levels and almost nobody gets tested for. Here’s what the new evidence says, what to do if your number is high, and the aspirin advice you should stop following.
I knew statins worked. I did not know how strange the origin story was. How statins started with mold The first statin came from Akira Endo, a Japanese biochemist who grew up fascinated by fungi and was inspired by the discovery of penicillin. After spending time in New York in the 1960s, he was struck
If you have Medicare and your doctor has been telling you about a new daily pill for weight loss, this post is for you. Foundayo is real, it’s FDA-approved, and starting July 1, 2026, it’s covered for $50 a month under Medicare’s GLP-1 Bridge program for eligible beneficiaries. This is genuinely new. Foundayo got FDA
Starting July 1, 2026, Medicare will cover Wegovy, Zepbound and Foundayo for obesity at a $50 monthly copay. The program is real, it’s called the Medicare GLP-1 Bridge, and it runs through December 31, 2027. I’m lucky — my employer’s insurance covers Zepbound, and I’ve been on it long enough to learn the system the
Quick disclosure first. I take Zepbound at 12.5mg, prescribed by my doctor and covered by insurance. If the coverage went away tomorrow I’d be on LillyDirect cash-pay before the end of the week. That’s where I’m coming from. I admit I am fascinated by the rise of peptides. It’s as much a business story as
I read a USA Today story this week about the rise of “biohacking,” and my first reaction was that it mostly got the vibe right. More wearables. More self-ordered labs. More biological-age tests. More longevity clinics. More guys showing up with a screen full of numbers and the feeling that they’re finally getting serious about
I quit drinking after getting headaches, looking at the evidence and deciding it wasn’t worth it. Most people with alcohol use disorder can’t just decide. Fewer than 2% of them ever get medication for it, and the drugs we do have (naltrexone, acamprosate, disulfiram) produce small effects and get almost no uptake. This drug could
My answer: If you are losing a lot of weight on a GLP-1 drug like Zepbound, a DEXA scan can be worth it because it shows what the scale cannot: fat loss, lean mass, visceral fat, and fat distribution. In my case, the scale said I lost 35 lb over six months. DEXA showed something
A lot of health advice online still pushes the same basic fantasy: that one big change is going to transform your future. Alternatively there is the biohackers hustle culture demanding to “optimize” everything right now. For many folks that’s so intimidating to be impossible. Personally, I have taken a somewhat staged approach while making small
